GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » ROA %

Redhill Biopharma (Redhill Biopharma) ROA % : 6.49% (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Redhill Biopharma's annualized Net Income for the quarter that ended in Jun. 2023 was $3.04 Mil. Redhill Biopharma's average Total Assets over the quarter that ended in Jun. 2023 was $46.94 Mil. Therefore, Redhill Biopharma's annualized ROA % for the quarter that ended in Jun. 2023 was 6.49%.

The historical rank and industry rank for Redhill Biopharma's ROA % or its related term are showing as below:

RDHL' s ROA % Range Over the Past 10 Years
Min: -69.24   Med: -51.84   Max: 26.29
Current: 16.78

During the past 13 years, Redhill Biopharma's highest ROA % was 26.29%. The lowest was -69.24%. And the median was -51.84%.

RDHL's ROA % is ranked better than
95.11% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.72 vs RDHL: 16.78

Redhill Biopharma ROA % Historical Data

The historical data trend for Redhill Biopharma's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma ROA % Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -61.98 -59.90 -54.09 -42.15 26.29

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.84 -9.44 184.62 6.49 -

Competitive Comparison of Redhill Biopharma's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's ROA % distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's ROA % falls into.



Redhill Biopharma ROA % Calculation

Redhill Biopharma's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=23.916/( (158.87+23.047)/ 2 )
=23.916/90.9585
=26.29 %

Redhill Biopharma's annualized ROA % for the quarter that ended in Jun. 2023 is calculated as:

ROA %=Net Income (Q: Jun. 2023 )/( (Total Assets (Q: Mar. 2023 )+Total Assets (Q: Jun. 2023 ))/ count )
=3.044/( (58.834+35.037)/ 2 )
=3.044/46.9355
=6.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2023) net income data. ROA % is displayed in the 30-year financial page.


Redhill Biopharma  (NAS:RDHL) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2023 )
=Net Income/Total Assets
=3.044/46.9355
=(Net Income / Revenue)*(Revenue / Total Assets)
=(3.044 / 7.184)*(7.184 / 46.9355)
=Net Margin %*Asset Turnover
=42.37 %*0.1531
=6.49 %

Note: The Net Income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Redhill Biopharma ROA % Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.